Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Arcus Biosciences (NYSE:RCUS) had its price objective upped by stock analysts at The Goldman Sachs Group from $30.00 to $34.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective points to a potential upside of 34.00% from the stock’s previous close.

A number of other equities analysts have also recently commented on the company. Truist Financial upgraded Arcus Biosciences to a “strong-buy” rating in a report on Monday, May 4th. Morgan Stanley restated an “equal weight” rating and set a $20.00 target price (down from $23.00) on shares of Arcus Biosciences in a report on Thursday, January 8th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 2nd. Leerink Partners set a $47.00 target price on shares of Arcus Biosciences in a research note on Monday, April 20th. Finally, Citigroup raised their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average target price of $33.11.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $25.37 on Thursday. The business has a 50-day moving average of $22.93 and a 200 day moving average of $22.10. Arcus Biosciences has a 12 month low of $7.91 and a 12 month high of $28.72. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of -7.98 and a beta of 0.87. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.36.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The firm had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. During the same quarter last year, the business earned ($1.14) earnings per share. The business’s revenue was down 39.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Arcus Biosciences will post -3.55 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV acquired a new stake in shares of Arcus Biosciences during the 1st quarter worth about $50,000. Swiss National Bank raised its position in shares of Arcus Biosciences by 2.0% during the 1st quarter. Swiss National Bank now owns 171,296 shares of the company’s stock worth $3,700,000 after acquiring an additional 3,300 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Arcus Biosciences by 11.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,041 shares of the company’s stock worth $460,000 after acquiring an additional 2,168 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Arcus Biosciences by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 511,166 shares of the company’s stock worth $11,041,000 after acquiring an additional 6,704 shares in the last quarter. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Arcus Biosciences during the 1st quarter worth about $783,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Goldman Sachs raised its price target on Arcus Biosciences to $34 from $30 and maintained a buy rating, signaling greater confidence in upside potential.
• Positive Sentiment: HC Wainwright increased several earnings estimates for 2026, 2027, 2029 and 2030, including a higher FY2030 profit forecast, while keeping a buy rating and $32 target.
• Positive Sentiment: Arcus said PEAK-1 enrollment should be complete by year-end 2026 and that its cash runway extends into the second half of 2028, which may ease dilution worries. Article Title
• Neutral Sentiment: HC Wainwright did trim some longer-term estimates, including FY2026, FY2027 and FY2028 EPS, showing that the path to profitability remains challenging despite the higher targets.
• Neutral Sentiment: The company remains deeply unprofitable, and recent earnings results were weaker than expected, so investors are still watching for clinical and operating progress.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.